777 related articles for article (PubMed ID: 26577683)
1. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
[TBL] [Abstract][Full Text] [Related]
2. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
[TBL] [Abstract][Full Text] [Related]
4. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
[TBL] [Abstract][Full Text] [Related]
5. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
[TBL] [Abstract][Full Text] [Related]
6. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
Rubin DT; Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Sale ME; Rolleri RL; Golden PL; Barrett AC; Bortey E; Forbes WP
Dig Dis Sci; 2015 Nov; 60(11):3408-17. PubMed ID: 26386854
[TBL] [Abstract][Full Text] [Related]
7. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Clemmons DR; Golden PL; Rolleri RL; Yu J; Barrett AC; Bortey E; Paterson C; Forbes WP
Gastroenterology; 2015 Apr; 148(4):740-750.e2. PubMed ID: 25644096
[TBL] [Abstract][Full Text] [Related]
8. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
[TBL] [Abstract][Full Text] [Related]
9. Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Kruis W; Siegmund B; Lesniakowski K; Simanenkov V; Khimion L; Sobon M; Delmans G; Maksyashina SV; Sablin OA; Pokrotnieks J; Mostovoy Y; Datsenko O; Abdulkhakov S; Dorofeyev A; Levchenko O; Alexeeva O; Andreev P; Kolesnik IP; Mihaly E; Abrahamovych O; Baluta M; Kharchenko N; Viacheslav N; Uspenskiy Y; Vieth M; Mohrbacher R; Mueller R; Greinwald R
J Crohns Colitis; 2022 Nov; 16(11):1714-1724. PubMed ID: 35709376
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
[TBL] [Abstract][Full Text] [Related]
11. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
12. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
[TBL] [Abstract][Full Text] [Related]
13. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis.
Lindgren S; Löfberg R; Bergholm L; Hellblom M; Carling L; Ung KA; Schiöler R; Unge P; Wallin C; Ström M; Persson T; Suhr OB
Scand J Gastroenterol; 2002 Jun; 37(6):705-10. PubMed ID: 12126250
[TBL] [Abstract][Full Text] [Related]
14. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H;
Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749
[TBL] [Abstract][Full Text] [Related]
15. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.
Lichtenstein GR; Travis S; Danese S; D'Haens G; Moro L; Jones R; Huang M; Ballard ED; Bagin R; Hardiman Y; Collazo R; Sandborn WJ
J Crohns Colitis; 2015 Sep; 9(9):738-46. PubMed ID: 26094251
[TBL] [Abstract][Full Text] [Related]
16. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
17. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings.
Kobayashi K; Hirai F; Naganuma M; Watanabe K; Ando T; Nakase H; Matsuoka K; Watanabe M
J Crohns Colitis; 2014 Nov; 8(11):1444-53. PubMed ID: 24923656
[TBL] [Abstract][Full Text] [Related]
20. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
